Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Clinical trial NCT03036124 · COMPLETED

Trial details

NCT number: NCT03036124
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Start date: 2017-02-08
Primary completion: 2019-07-17
Enrollment: 4744

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.